Doctor profile · Federal record
Dr. CHARLES TAYLOR, M.D.
Hematology & Oncology Physician (CMS: MEDICAL ONCOLOGY) · Hematology & Oncology Physician · TULSA, OK
- NPI 1003859679
- Accepts Medicare
- MIPS 82.5 / 100 · 2023
- 44 yrs in practice
- Licensed in 2 states
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
12697 E 51ST ST
TULSA, OK 741466236
(918) 505-3200
fax (918) 505-3253
Credentials & registration
- NPI registered
- June 2006 — 20 yrs on file
- Profile last updated
- May 1, 2015
- Year of graduation
- 1982 — 44 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State licenses (2)
- Oklahoma #14470 · Arizona #15268
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1003859679. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
171,225
Distinct HCPCS
10
Medicare allowed
$2,885,271
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1439 |
Injection, ferric carboxymaltose, 1 mg | 21,750 | 26 | $1 | |
J9299 |
Injection, nivolumab, 1 mg | 20,160 | 31 | $30 | |
Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 13,200 | 148 | $0 | |
J9267 |
Injection, paclitaxel, 1 mg | 12,187 | 42 | $0 | |
J1627 |
Injection, granisetron, extended-release, 0.1 mg | 11,300 | 81 | $6 | |
J9271 |
Injection, pembrolizumab, 1 mg | 11,200 | 30 | $51 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 10,100 | 26 | $0 | |
Q5110 |
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 9,540 | 13 | $0 | |
J0185 |
Injection, aprepitant, 1 mg | 8,190 | 48 | $2 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,660 | 21 | $48 |
In context: peer comparison
Among 18 peers in this city , average services per provider: 1,283. This provider delivers 133× the peer median.Open Payments
Industry payments received
All-time total
$195
Transactions
9
Manufacturers
6
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 3 | $48.69 | |
| PFIZER INC. | 2 | $39.17 | |
| Genmab U.S., Inc. | 1 | $33.16 | |
| E.R. Squibb & Sons, L.L.C. | 1 | $28.96 | |
| GENZYME CORPORATION | 1 | $25.37 | |
| Agios Pharmaceuticals, Inc. | 1 | $19.38 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,498
Patients
320
Total drug cost
$2,433,244
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 447 | 84 | $6,269 |
| Exemestane | Generic | 195 | 35 | $25,493 |
| Anastrozole | Generic | 127 | 30 | $2,125 |
| Ibrance (Palbociclib) | Brand | 93 | 11 | $1,297,664 |
| Tamoxifen Citrate | Generic | 90 | 24 | $2,485 |
| Dexamethasone | Generic | 63 | 17 | $916 |
| Potassium Chloride | Generic | 61 | 20 | $1,266 |
| Ondansetron Odt (Ondansetron) | Brand | 59 | 27 | $985 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 58 | 22 | $935 |
| Revlimid (Lenalidomide) | Brand | 56 | 0 | $1,091,422 |